If you run clinical programming on SAS, you have probably seen SAS Clinical Acceleration in the last few months. If you have not, you are likely to.
We have discussed it with many of you, on calls, at events and in platform planning workshops. This article sets out what the product does, where it needs scrutiny and what to ask before you commit.
Our position: Katalyze Data is a SAS Gold Partner and was SAS’s Global Solution Partner of the Year in 2025. We are also a Posit Premier Partner, and we build and validate environments on both.
Clinical data is difficult because every number has to be defensible. It must be traceable to source, produced by a documented process, reproducible by someone other than the author of the code, and generated in an environment that a regulator accepts as controlled.
Data arrives from many sources: EDC, CDMS, central and local labs, imaging vendors, wearables and the CROs attached to the programme. Formats, delivery schedules and access models differ.
Many organisations manage this with a combination of tools. A validated SAS or R environment handles the transformation to SDTM and ADaM and the production of TFLs. SharePoint or a file share holds everything else. A spreadsheet tracks which version of each file is current. A period of reconciliation before database lock follows, which is rarely planned but usually expected.
The cost shows up as time: identifying which ADaM dataset fed which table, re-running analyses because an environment changed, and assembling documentation that should have been generated as the work was done.
The platform is intended to replace that combination of tools with a single environment. It is cloud native and built on SAS Viya. It combines a governed content repository for clinical research data and documents with a statistical computing environment for analysing them. It provides one audit record and lineage from source data to the output you submit. For most teams, that is the main reason to consider it.
Two further components sit on top: SAS Clinical Job Management and Clinical Workflows. Clinical Workflows is built on SAS Workflow Manager and has a BPMN-based designer. This is where the automation sits: orchestrating and scheduling programming work, not only storing its inputs and outputs.
It is sold in two modules, which affects the commercial discussion:
The dependency runs one way. The full platform requires the repository, but the repository does not require the full platform. Buying the repository first and upgrading later is therefore a valid sequence.
The compliance capability is solid and largely as expected. It includes role-based privileges, groups and permissions, electronic signatures, version control, check-in and check-out, full-text search, and an audit trail that records what changed, when and by whom, all mapped to FDA 21 CFR Part 11.
Two points matter most.
The repository holds everything, not only datasets. It covers programs, specifications, define files, PDFs and output. Governance has limited value if only part of your material sits inside it. If programs are versioned but the specification they were written against sits on a shared drive, there is a gap, and it is the kind of gap that inspections find.
Lineage traces back to source. This turns a regulator’s mid-review question from three days of searching into an afternoon’s work.
An increasing amount of clinical programming is being performed using R and Python over the last decade. A common problem follows. Open source work happens outside the validated environment and is then re-implemented in SAS so that it can be submitted. This doubles the effort and adds risk.
Clinical Acceleration supports all three languages inside the governed environment. The analysis and the auditable record are the same artefact.
Python has been native to Viya for some time. R support has changed more recently:
Multi-language support is not unique to this product. It is a baseline expectation for a modern SCE and is what Posit Workbench and other platforms are built around. For organisations already standardised on SAS, it removes a reason to run a second platform alongside.
SAS makes its most forward-looking claims about these two standards, so it is worth understanding what they are.
Dataset-JSON is CDISC’s modern alternative to the SAS XPT transport format, which has carried submissions for decades. XPT has three limits:
Dataset-JSON removes these limits and compresses better. Version 1.1 was released in December 2024. In April 2025, the FDA issued a Federal Register notice inviting comment on it as a long term replacement for XPT.
CDISC CORE, the CDISC Open Rules Engine, publishes conformance rules as executable, machine readable, open source code. Without it, each sponsor and CRO interprets rules written as prose, and the interpretations differ slightly. CORE allows conformance to be checked continuously through a study rather than only at the end, which surfaces integrity problems months earlier. CORE v1.0 was targeted for mid 2026.
SAS states that Clinical Acceleration complies with both. Neither is mandated yet, so this is insurance rather than immediate return. If the FDA sets a timeline, you would not be starting a tooling migration from the beginning. The value is real but deferred.
There are three hosting options:
If SAS hosts the platform, SAS sets the release cadence, not you. This is SAS’s stated policy for software-as-a-service customers. In practice:
If a specific feature matters to your timeline, confirm which release you will be on.
The platform connects to EDC, CDMSs, lab feeds, CRO data, validation tools and metadata repositories. Access is not limited to SAS tooling:
If your MDR is the source of truth for your standards, ask how closely it connects. The answer determines whether standards governance is automated or depends on manual work.
Feature lists are rarely where a move goes wrong. Problems come from work that was not scoped. If you are moving from an existing validated environment, the following has to be addressed.
Content and folder hierarchies. These are rarely a straight copy. Existing structures reflect a decade of assumptions about who sees what and where each study sits. Restate those assumptions in the new model rather than copying them across.
Permission models. Migrations often overrun here. The mapping looks simple on a plan and is difficult in practice. It covers:
Macro libraries. Most organisations have more than they expect, and many are undocumented. You need:
Job flows and scheduling. Dependencies between jobs are often the least documented part of an estate. They tend to surface late.
Parallel-run validation. The most credible evidence is to run both environments on the same inputs and reconcile the outputs. Record the reasoning for each difference. This needs a proper budget.
Who does the work. The vendor, a partner or your own team can each do it. The choice changes the timeline and cost substantially. Settle it before you sign.
Duration. We have stood up and validated environments in as little as six weeks, including IQ, OQ and PQ, configuration and knowledge transfer. Where your project lands depends on:
The factor most often under-budgeted is the availability of your own subject matter experts. The installation itself is rarely the variable.
If you built your current environment yourselves, there is a further change. You move from infrastructure you control to infrastructure a vendor controls. There is less to maintain, and also less you can change.
It is likely a good fit if:
We would steer you elsewhere, or advise a slower approach, if:
These are the eight questions we put to vendors on behalf of clients.